UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 27, 2024 |
Pyxis Oncology, Inc.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-40881 | 83-1160910 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
321 Harrison Avenue | |
Boston, Massachusetts | | 02118 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 617-221-9059 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share | | PYXS | | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events.
On March 27, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing that the Company entered into an agreement with Novartis Technology LLC (“Novartis”) for the sale of its rights to royalties from the commercialization of Beovu® (brolucizumab-dbll) and another asset for a one-time cash payment of $8 million. Additionally, all royalties previously received by Apexigen, Inc. (“Apexigen”) and the Company from Novartis will be free from any reclaim rights.
In August 2023, the Company completed the acquisition of Apexigen and assumed all out-licensing agreements of Apexigen, including rights to royalties on sales of Beovu® and another asset discovered using the APXiMAB Platform, Apexigen's proprietary antibody discovery platform.
A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | | Pyxis Oncology, Inc. |
| | | |
Date: | March 27, 2024 | By: | /s/ Pamela Connealy |
| | | Pamela Connealy
Chief Financial Officer and Chief Operating Officer |
